Study on cell matrix of pancreatic duct adenocarcinoma

doi:10.3760/cma.j.issn.1673-422X.2018.11.013

Journal of International Oncology ›› 2018, Vol. 45 ›› Issue (11): 696-698.doi: 10.3760/cma.j.issn.1673-422X.2018.11.013

Previous Articles Next Articles

Study on cell matrix of pancreatic duct adenocarcinoma

Xing Rongchun， Qin Zhouping

Department of Emergency and Trauma Surgery, First College of Clinical Medical Sciences, China Three Gorges University, Yichang 443003, China

Online:2018-11-08 Published:2018-12-21
Contact: Xing Rongchun, Email: xingrongchun@sina.com E-mail:xingrongchun@sina.com

Abstract

Abstract: The occurrence of pancreatic duct adenocarcinoma (PDAC) is closely related to the biological immunological characteristics of the hematopoietic matrix of its cancer cells. The malignant characteristics of the cancer matrix play important roles in the malignant origin of tumors, avoiding immune surveillance, promoting tumor progression and growth, and increasing drug resistance and metastasis. Understanding the important roles of hyaluronic acid, Sonic Hedgehog signaling pathway, transforming growth factor-beta, CD40, Kras pathway and microRNA in the pathogenesis and development of PDAC, can provide new strategies for clinical treatment of PDAC.

Key words: Carcinoma, pancreatic ductal, Signal transduction, Extracellular matrix, Tumor microenvironment

Xing Rongchun， Qin Zhouping. Study on cell matrix of pancreatic duct adenocarcinoma[J]. Journal of International Oncology, 2018, 45(11): 696-698.

[1]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.
[2]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[3]	Liu Xiaodi, Su Jianfei, Zhang Jingxian, Wei Xueqin, Jia Yingjie. Research progress of myeloid-derived suppressor cells in tumor angiogenesis [J]. Journal of International Oncology, 2024, 51(1): 50-54.
[4]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[5]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng. Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance [J]. Journal of International Oncology, 2023, 50(4): 227-230.
[6]	Ding Hao, Ying Jintao, Fu Maoyong. Research progress of CAR-T in the treatment of esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(4): 231-235.
[7]	Cao Mengqing, Xu Zhiyong, Shi Yuting, Wang Kai. Role of tertiary lymphoid structures in tumor immune microenvironment regulation and anti-tumor therapy [J]. Journal of International Oncology, 2023, 50(3): 169-173.
[8]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[9]	Zhu Yi, Chen Jian. Mechanism of hydrogen sulfide in tumorigenesis and development and its donor-mediated anti-tumor effects [J]. Journal of International Oncology, 2023, 50(12): 729-733.
[10]	Xie Lulu, Ding Jianghua. Progress of immunotherapy-based strategy in triple-negative breast cancer [J]. Journal of International Oncology, 2023, 50(11): 672-676.
[11]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[12]	Ma Xueyan, Lu Lili, Sun Pengfei. Advances in the immune microenvironment in cervical cancer [J]. Journal of International Oncology, 2023, 50(1): 47-50.
[13]	Wu Jiayu, Liu Jiacheng. Research progress of radiomics toward lung adenocarcinoma manifesting as solitary ground glass nodule [J]. Journal of International Oncology, 2022, 49(8): 449-452.
[14]	Zhang Zishu, Wu Xinlin. Mechanism of action of lactic acid in tumor microenvironment and related treatment [J]. Journal of International Oncology, 2022, 49(6): 349-352.
[15]	Wu Jiayi, Chen Keyu, Shao Xiying, Wang Xiaojia. Research progress on the mechanism of CDK4/6 inhibitors promoting antitumor immunity by regulating the immune microenvironment of triple negative breast cancer [J]. Journal of International Oncology, 2022, 49(6): 362-365.

Study on cell matrix of pancreatic duct adenocarcinoma

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments